MedicineNews.net

HER2-positive breast cancer: Neratinib, little benefit and severe toxicity

The FDA ( U.S. Food and Drug Administration ) has approved 1 year of extended adjuvant Neratinib ( Nerlynx ) after chemotherapy and a year of Trastuzumab ( Herceptin ) for HER2-positive breast cancer ... read article

Advanced BRCA-related breast cancer: Olaparib, a PARP inhibitor, is superior to chemotherapy

During the American Society of Clinical Oncology ( ASCO ) Annual Meeting, the results of the phase III OlympiAD trial demonstrating for the first time that Olaparib ( Lynparza ) is superior to chemoth ... read article

Breast cancer may be more aggressive in patients with obesity

Women with obesity are more likely to get breast cancer, and a number of studies have provided a reasonable explanation why: after menopause, fat tissue manufactures estrogen, and the estrogen then pr ... read article

Capecitabine, an anticancer agent, associated with risk of severe skin reactions

Capecitabine ( Xeloda ) is a first-line, adjuvant, or combination treatment for colon cancer, and for metastatic colorectal cancer, gastric cancer, or breast cancer. Skin reactions associated with ... read article

European Commission: indication expansion of Halaven for advanced or metastatic breast cancer after only one prior chemotherapy

Eisai has announced that it has received approval from the European Commission ( EC ) of the indication expansion of Halaven ( Eribulin mesylate ) to contribute to earlier treatment of patients with l ... read article

New formulation of Herceptin approved in Europe for the treatment of HER2-positive breast cancer

Roche has announced that a new injectable ( subcutaneous ) formulation of Herceptin ( Trastuzumab ) has been approved by the European Commission for the treatment of HER2-positive breast cancer, an ag ... read article

Forxiga, a SGLT2 inhibitor, approved in Europe for treatment of type 2 diabetes

Forxiga ( Dapagliflozin ) is the first SGLT2 ( sodium/glucose cotransporter 2 ) class drug. Forxiga has obtained marketing approval by the European Commission ( EC ) for the treatment of type 2 diabet ... read article

Pertuzumab for the treatment of patients with HER2-positive metastatic breast cancer

The FDA ( Food and Drug Administration ) has approved Pertuzumab injection ( Perjeta ) for use in combination with Trastuzumab and Docetaxel for the treatment of patients with HER2-positive metastatic ... read article

Anti-angiogenesis treatments: Bevacizumab, Sunitinib increase breast cancer stem cells

Cancer treatments designed to block the growth of blood vessels were found to increase the number of cancer stem cells in breast tumors in mice, suggesting a possible explanation for why these drugs d ... read article

Lantus associated with an increased risk for breast cancer

Having diabetes or being obese after age 60 significantly increases the risk for developing breast cancer, a Swedish study has revealed. Data also showed that high blood lipids were less common in pat ... read article

Type 2 diabetes patients inadequately controlled with Metformin: safety and efficacy of Dapagliflozin plus Metformin at 102 weeks

Bristol-Myers Squibb ( BMS ) and AstraZeneca have announced results from an exploratory 78-week study extension of a phase 3 clinical study that showed the investigational compound Dapagliflozin plus ... read article

Zometa does not reduce the recurrences of breast cancer

A trial investigating the use of Zoledronic acid ( Zoledronate; Zometa ) to aid chemotherapy for breast cancer has not found a significant benefit for reducing the risk of recurrence. Zometa should n ... read article

Risk of osteonecrosis of the jaw associated with Bevacizumab and Sunitinib

Treatment with Bevacizumab or Sunitinib may be a risk factor for the development of osteonecrosis of the jaw, particularly if a patient has previously received, or is treated concurrently with, bispho ... read article

Xgeva for preventing cancer-related bone injury, FDA approved

The FDA ( Food and Drug Administration ) has approved Xgeva ( Denosumab ) to help prevent skeletal-related events ( SREs ) in patients with cancer that has metastasized and damaged the bone. Skeletal- ... read article

Trastuzumab-DM1 as a first-line therapy in HER2+ metastatic breast cancer

A new type of breast cancer treatment has shown encouraging activity as a first-line therapy in HER2-positive metastatic disease. Edith Perez, Mayo Clinic in Florida, presented the results of the f ... read article